MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- Compare Company
- Indian - pharmaceuticals
- ASTRAZENECA PHARMA - DISHMAN PHARMA
ASTRAZENECA PHARMA vs DISHMAN PHARMA - Comparison Results
ASTRAZENECA PHARMA Change
AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More
DISHMAN PHARMA 
Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
Current Valuations
| ASTRAZENECA PHARMA | DISHMAN PHARMA | ASTRAZENECA PHARMA/ DISHMAN PHARMA |
|||
|---|---|---|---|---|---|
| P/E (TTM) | x | 109.6 | 25.1 | 436.9% | View Chart |
| P/BV | x | 33.6 | 3.3 | 1,002.6% | View Chart |
| Dividend Yield | % | 0.0 | 0.7 | - |
Financials
 ASTRAZENECA PHARMA  DISHMAN PHARMA |
| EQUITY SHARE DATA | |||||
|---|---|---|---|---|---|
| ASTRAZENECA PHARMA Mar-18 |
DISHMAN PHARMA Mar-16 |
ASTRAZENECA PHARMA/ DISHMAN PHARMA |
5-Yr Chart Click to enlarge
|
||
| High | Rs | 1,278 | 374 | 341.3% | |
| Low | Rs | 883 | 129 | 684.7% | |
| Sales per share (Unadj.) | Rs | 228.4 | 197.8 | 115.5% | |
| Earnings per share (Unadj.) | Rs | 10.4 | 21.2 | 48.9% | |
| Cash flow per share (Unadj.) | Rs | 16.3 | 34.7 | 46.8% | |
| Dividends per share (Unadj.) | Rs | 0 | 2.00 | 0.0% | |
| Dividend yield (eoy) | % | 0 | 0.8 | 0.0% | |
| Book value per share (Unadj.) | Rs | 98.8 | 179.9 | 54.9% | |
| Shares outstanding (eoy) | m | 25.00 | 80.69 | 31.0% | |
| Bonus/Rights/Conversions | - | - | - | ||
| Price / Sales ratio | x | 4.7 | 1.3 | 371.8% | |
| Avg P/E ratio | x | 104.2 | 11.9 | 878.4% | |
| P/CF ratio (eoy) | x | 66.4 | 7.2 | 916.7% | |
| Price / Book Value ratio | x | 10.9 | 1.4 | 781.9% | |
| Dividend payout | % | 0 | 9.4 | 0.0% | |
| Avg Mkt Cap | Rs m | 27,008 | 20,306 | 133.0% | |
| No. of employees | `000 | 1.4 | 0.8 | 163.6% | |
| Total wages/salary | Rs m | 1,535 | 5,355 | 28.7% | |
| Avg. sales/employee | Rs Th | 4,210.9 | 19,252.7 | 21.9% | |
| Avg. wages/employee | Rs Th | 1,132.2 | 6,459.5 | 17.5% | |
| Avg. net profit/employee | Rs Th | 191.1 | 2,064.1 | 9.3% | |
| INCOME DATA | |||||
|---|---|---|---|---|---|
| Net Sales | Rs m | 5,710 | 15,961 | 35.8% | |
| Other income | Rs m | 123 | 265 | 46.2% | |
| Total revenues | Rs m | 5,833 | 16,226 | 35.9% | |
| Gross profit | Rs m | 463 | 4,103 | 11.3% | |
| Depreciation | Rs m | 147 | 1,091 | 13.5% | |
| Interest | Rs m | 0 | 944 | 0.0% | |
| Profit before tax | Rs m | 438 | 2,334 | 18.8% | |
| Minority Interest | Rs m | 0 | 0 | - | |
| Prior Period Items | Rs m | 0 | 1 | 0.0% | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
| Tax | Rs m | 179 | 624 | 28.7% | |
| Profit after tax | Rs m | 259 | 1,711 | 15.1% | |
| Gross profit margin | % | 8.1 | 25.7 | 31.5% | |
| Effective tax rate | % | 40.8 | 26.7 | 152.8% | |
| Net profit margin | % | 4.5 | 10.7 | 42.3% | |
| BALANCE SHEET DATA | |||||
|---|---|---|---|---|---|
| Current assets | Rs m | 3,209 | 11,018 | 29.1% | |
| Current liabilities | Rs m | 2,070 | 9,517 | 21.7% | |
| Net working cap to sales | % | 20.0 | 9.4 | 212.3% | |
| Current ratio | x | 1.6 | 1.2 | 133.9% | |
| Inventory Days | Days | 72 | 110 | 65.5% | |
| Debtors Days | Days | 35 | 35 | 100.2% | |
| Net fixed assets | Rs m | 790 | 16,304 | 4.8% | |
| Share capital | Rs m | 50 | 161 | 31.0% | |
| "Free" reserves | Rs m | 2,419 | 12,907 | 18.7% | |
| Net worth | Rs m | 2,469 | 14,516 | 17.0% | |
| Long term debt | Rs m | 0 | 4,189 | 0.0% | |
| Total assets | Rs m | 4,605 | 29,805 | 15.5% | |
| Interest coverage | x | NM | 3.5 | - | |
| Debt to equity ratio | x | 0 | 0.3 | 0.0% | |
| Sales to assets ratio | x | 1.2 | 0.5 | 231.5% | |
| Return on assets | % | 5.6 | 8.9 | 63.1% | |
| Return on equity | % | 10.5 | 11.8 | 89.0% | |
| Return on capital | % | 17.7 | 17.5 | 101.2% | |
| Exports to sales | % | 0 | 24.8 | 0.0% | |
| Imports to sales | % | 0 | 3.7 | 0.0% | |
| Exports (fob) | Rs m | NA | 3,956 | 0.0% | |
| Imports (cif) | Rs m | NA | 596 | 0.0% | |
| Fx inflow | Rs m | 300 | 4,952 | 6.0% | |
| Fx outflow | Rs m | 2,015 | 697 | 289.2% | |
| Net fx | Rs m | -1,715 | 4,255 | -40.3% | |
| CASH FLOW | |||||
|---|---|---|---|---|---|
| From Operations | Rs m | 88 | 2,786 | 3.2% | |
| From Investments | Rs m | -94 | -1,529 | 6.1% | |
| From Financial Activity | Rs m | NA | -941 | 0.0% | |
| Net Cashflow | Rs m | -6 | 316 | -1.8% | |
Share Holding
| Indian Promoters | % | 0.0 | 61.4 | - | |
| Foreign collaborators | % | 75.0 | 0.0 | - | |
| Indian inst/Mut Fund | % | 0.3 | 3.7 | 8.1% | |
| FIIs | % | 15.7 | 12.7 | 123.6% | |
| ADR/GDR | % | 0.0 | 0.0 | - | |
| Free float | % | 9.1 | 22.1 | 41.2% | |
| Shareholders | 12,856 | 46,261 | 27.8% | ||
| Pledged promoter(s) holding | % | 0.0 | 35.8 | - |
Compare ASTRAZENECA PHARMA With: ELDER PHARMA FDC SUN PHARMA STRIDES PHARMA SCIENCE TTK HEALTHCARE
Compare ASTRAZENECA PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Today's Market
Sensex Ends 154 Points Lower, Nifty Ends at 14,834; Bajaj Finance and UPL Among Top Losers(Closing)
Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.
Related Views on News
ASTRAZENECA PHARMA Announces Quarterly Results (3QFY21); Net Profit Down 21.2% (Quarterly Result Update)
Feb 11, 2021 | Updated on Feb 11, 2021For the quarter ended December 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 211 m (down 21.2% YoY). Sales on the other hand came in at Rs 2 bn (down 10.5% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)
Sep 22, 2020 | Updated on Sep 22, 2020For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)
May 20, 2020 | Updated on May 20, 2020For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)
Aug 8, 2019 | Updated on Aug 8, 2019For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)
May 27, 2019 | Updated on May 27, 2019For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.
More Views on NewsMost Popular
A Critical Update on the Market(Fast Profits Daily)
Mar 30, 2021In this video, I'll tell you why I am recommending caution in the market at this time.
My Recent Recommendation Will Profit from the Global Supply Chain Crisis(Profit Hunter)
Mar 31, 2021A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.
My Stock Trading Strategy(Fast Profits Daily)
Mar 31, 2021In this video I'll show you exactly how I go about picking stocks for trading.
What You Need to Find Hundred Baggers(Profit Hunter)
Mar 30, 2021100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.
MoreOUR TOP 5 IDEAS
- India's Revival: A Once-in-a-generation Wealth Making Opportunity
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
ASTRAZENECA PHARMA SHARE PRICE
Apr 9, 2021 (Close)
TRACK ASTRAZENECA PHARMA
- Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON ASTRAZENECA PHARMA
ASTRAZENECA PHARMA 5-YR ANALYSIS
COMPARE ASTRAZENECA PHARMA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Momentum Moves
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.